Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
8yCtf1eHEgbpAJv6